First Time Loading...
P

POINT Biopharma Global Inc
NASDAQ:PNT

Watchlist Manager
POINT Biopharma Global Inc
NASDAQ:PNT
Watchlist
Price: 12.5 USD Market Closed
Updated: May 4, 2024

POINT Biopharma Global Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

POINT Biopharma Global Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
P
POINT Biopharma Global Inc
NASDAQ:PNT
Revenue
$226.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.5B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

POINT Biopharma Global Inc
Revenue Breakdown

Breakdown by Geography
POINT Biopharma Global Inc

Not Available

Breakdown by Segments
POINT Biopharma Global Inc

Total Revenue: 226.6m USD
100%
License Revenue: 225.2m USD
99.4%
Other Revenue: 1.4m USD
0.6%

See Also

What is POINT Biopharma Global Inc's Revenue?
Revenue
226.6m USD

Based on the financial report for Dec 31, 2022, POINT Biopharma Global Inc's Revenue amounts to 226.6m USD.